厄贝沙坦对高血压合并心力衰竭病人的临床疗效及对hs-CRP、BNP水平变化的影响

目的研究厄贝沙坦对高血压合并心力衰竭(HHF)病人的临床疗效及对超敏型C反应蛋白(hs-CRP)、脑利钠肽(BNP)水平变化的影响。方法选择2012年2月到2013年2月我院88例HHF患者并随机分成两组各44例。对照组患者均于入院后实施常规治疗,观察组在此基础上加用厄贝沙坦。对比两组疗效以及治疗前后hs-CRP和BNP水平变化的情况。结果观察组显效率为40.91%,总有效率为95.45%,均显著高于对照组(P<0.05)。观察组治疗后hs-CRP水平为(4.5±1.3)mg/L,BNP水平为(110.8±23.6)mg/L,均显著低于本组治疗前以及对照组治疗后,差异均有统计学意义(均P<0.05)。结论以厄贝沙坦治疗HHF患者,可较为明显地提升临床疗效,缓解患者hs-CRP以及BNP水平。

Effects of Irbesartan on the Clinical Efficacy and Changes of hs-CRP and BNP of Patients with Hypertensive Heart Failure

Objective To explore the effects of irbesartan on the clinical efficacy and changes of hs-CRP and BNP of patients with hypertensive heart failure （HHF）. Methods 88 patients with HHF in our hospital were randomly divided into two groups, with 44 cases in each group. The control group received routine therapy, while the observation group received irbesartan additionally. The clinical efficacy, changes of levels of hs-CRP and BNP before and after therapy of two groups were observed and compared. Results The mark effective rate and total effective rate of observation group were 40.91%and 95.45%respectively, significantly higher than those of control group （both P〈0.05）. The level of hs-CRP and level of BNP after therapy of observation group were significantly lower than those before therapy, and those after therapy of control group （all P〈0.05）. Conclusions Irbesartan can effectively improve the clinical effect of patients with HHF, in addition, it can reduce the levels of hs-CRP and BNP of patients.